Rapid testing for group B streptococcus during labour: A test accuracy study with evaluation of acceptability and cost-effectiveness

Health Technology Assessment

Volumn 13, Issue 42, 2009, Pages

  Daniels, J ^a   Gray, J ^b   Pattison, H ^c   Roberts, T ^a   Edwards, E ^b   Milner, P ^b   Spicer, L ^d   King, E ^a   Hills, R K ^a   Gray, R ^a   Buckley, L ^a   Magill, L ^a   Elliman, N ^c   Kaambwa, B ^a   Bryan, S ^a   Howard, R ^d   Thompson, P ^b   Khan, K S ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

^d HAVERING AND REDBRIDGE UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN G; VACCINE;

AGE DISTRIBUTION; ATTITUDE TO HEALTH; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM DETECTION; BIRTH; CESAREAN SECTION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DNA HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; ETHNICITY; FEVER; GESTATIONAL AGE; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LABOR; LATEX AGGLUTINATION TEST; MICROBIOLOGICAL EXAMINATION; MIDWIFE; NEWBORN CARE; NONHUMAN; OPTICAL IMMUNOASSAY; POLYMERASE CHAIN REACTION; PREDICTION; PREGNANT WOMAN; PREMATURE LABOR; QUESTIONNAIRE; RECTAL SWAB; REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SOUTH ASIA; STREPTOCOCCUS AGALACTIAE; SYSTEMATIC REVIEW; UNITED KINGDOM; VACCINATION; VAGINA SWAB; ADULT; AGE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; ETHNIC GROUP; FEMALE; ISOLATION AND PURIFICATION; LABOR COMPLICATION; MASS SCREENING; MICROBIOLOGY; NEWBORN; NEWBORN DISEASE; PARITY; PATIENT DROPOUTS; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; RECTUM; STATISTICS; STREPTOCOCCUS INFECTION; VAGINA; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIBIOTIC PROPHYLAXIS; ATTITUDE TO HEALTH; BACTERIOLOGICAL TECHNIQUES; COST-BENEFIT ANALYSIS; ETHNIC GROUPS; FEMALE; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; MASS SCREENING; MIDWIFERY; OBSTETRIC LABOR COMPLICATIONS; PARITY; PATIENT DROPOUTS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; RECTUM; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VAGINA; YOUNG ADULT;

EID: 70449578206     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta13420     Document Type: Review

References (167)

1. Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group. Obstet Gynecol 1991;77:604-610
2. Edwards MS, Baker CJ. Group B streptococcal infections. In Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. Philadelphia, PA: WB Saunders; 2001. pp. 1091-1156
3. Regan JA, Klebanoff MA, Nugent RP, Eschenbach DA, Blackwelder WC, Lou Y, et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996;174:1354-1360 (Pubitemid 26131160)
4. Boyer KM, Gadzala CA, Kelly PD, Burd LI, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. J Infect Dis 1983;148:802-809 (Pubitemid 14244265)
5. Reid TM. Emergence of group B streptococci in obstetric and perinatal infections. Br Med J 1975;2:533-535
6. Simpson AJ, Mawn JA, Heard SR. Assessment of two methods for rapid intrapartum detection of vaginal group B streptococcal colonisation. J Clin Pathol 1994;47:752-755
7. Needham JR. Neonatal group B streptococcus infections: laboratory and animal studies. Med Lab Sci 1982;39:261-270
8. Mhalu FS. Reservoir of group B streptococci in women in labour. Br Med J 1977;1:812. (Pubitemid 8060013)
9. Easmon CS, Hastings MJ, Clare AJ, Bloxham B, Marwood R, Rivers RP, et al. Nosocomial transmission of group B streptococci. Br Med J 1981;283:459-461
10. Murphy JF, Sykes G, Gardiner M, Hannan A, Verier Jones ER. Group B streptococcal carrier rate in pregnant women and their newborn infants. J Infect 1982;5:165-169 (Pubitemid 12035280)
11. Easmon CS, Hastings MJ, Neill J. Is group B streptococcal screening during pregnancy justified? Br J Obstet Gynaecol 1985;92:197-201. (Pubitemid 15146691)
12. Colbourn T, Gilbert R. An overview of the natural history of early onset group B streptococcal disease in the UK. Early Hum Dev 2007;83:149-156 (Pubitemid 46330641)
13. Dillon HC, Jr, Gray E, Pass MA, Gray BM. Anorectal and vaginal carriage of group B streptococci during pregnancy. J Infect Dis 1982;145:794-799 (Pubitemid 12088953)
14. Hoogkamp-Korstanje JA, Gerards LJ, Cats BP. Maternal carriage and neonatal acquisition of group B streptococci. J Infect Dis 1982;145:800-803 (Pubitemid 12088954)
15. Daugaard HO, Thomsen AC, Henriques U, Ostergaard A. Group B streptococci in the lower urogenital tract and late abortions. Am J Obstet Gynecol 1988;158:28-31. (Pubitemid 18043329)
16. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973;83:919-925
17. Lin FY, Weisman LE, Troendle J, Adams K. Prematurity is the major risk factor for late-onset group B streptococcus disease. J Infect Dis 2003;188:267-271
18. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004;363:292-294
19. Luck S, Torny M, d'Agapeyeff K, Pitt A, Heath P, Breathnach A, et al. Estimated early-onset group B streptococcal neonatal disease. Lancet 2003;361:1953-1954
20. Oddie S, Embleton ND. Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. BMJ 2002;325:308.
21. Adriaanse AH, Lagendijk I, Muytjens HL, Nijhuis JG, Kollee LA. Neonatal early onset group B streptococcal infection. A nine-year retrospective study in a tertiary care hospital. J Perinat Med 1996;24:531-538 (Pubitemid 26358605)
22. Beardsall K, Thompson MH, Mulla RJ. Neonatal group B streptococcal infection in South Bedfordshire, 1993-1998. Arch Dis Child Fetal Neonatal Ed 2000;82:F205-7.
23. Halliday E, Foote K, Dryden M, Heard M, Down R, Ward J. Universal maternal screening for neonatal group B streptococcal disease. Lancet 2000;356:1407-1408 (Pubitemid 30800211)
24. Mifsud AJ, Efstratiou A, Charlett A, Christine M. Early-onset neonatal group B streptococcal infection in London: 1990-1999. BJOG 2004;111:1006-1011
25. Moses LM, Heath PT, Wilkinson AR, Jeffery HE, Isaacs D. Early onset group B streptococcal neonatal infection in Oxford 1985-1996. Arch Dis Child Fetal Neonatal Ed 1998;79:F148-9.
26. Boyer KM, Gotoff SP. Antimicrobial prophylaxis of neonatal group B streptococcal sepsis. Clin Perinatol 1998;15:831-850
27. Persson K, Bjerre B, Elfstrom L, Polberger S, Forsgren A. Group B streptococci at delivery: high count in urine increases risk for neonatal colonization. Scand J Infect Dis 1986;18:525-531 (Pubitemid 17197948)
28. Wood EG, Dillon HC, Jr. A prospective study of group B streptococcal bacteriuria in pregnancy. Am J Obstet Gynecol 1981;140:515-520 (Pubitemid 11093131)
29. Hammoud MS, Al-Shemmari M, Thalib L, Al-Sweih N, Rashwan N, Devarajan LV, et al. Comparison between different types of surveillance samples for the detection of GBS colonization in both parturient mothers and their infants. Gynecol Obstet Invest 2003;56:225-230 (Pubitemid 37505855)
30. Al-Sweih N, Hammoud M, Al-Shimmiri M, Jamal M, Neil L, Rotimi V. Serotype distribution and mother-to-baby transmission rate of Streptococcus agalactiae among expectant mothers in Kuwait. Arch Gynecol Obstet 2005;272:131-135 (Pubitemid 40941748)
31. Laboratory practices for prenatal group B streptococcal screening and reporting - Connecticut, Georgia and Minnesota, 1997-1998. MMWR Morb Mortal Wkly Rep 1999;48:426-428
32. Rauen NC, Wesenberg EM, Cartwright CP. Comparison of selective and nonselective enrichment broth media for the detection of vaginal and anorectal colonization with group B streptococcus. Diagn Microbiol Infect Dis 2005;51:9-12.
33. Badri MS, Zawaneh S, Cruz AC, Mantilla G, Baer H, Spellacy WN, et al. Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. J Infect Dis 1977;135:308-312 (Pubitemid 8049544)
34. Philipson EH, Palermino DA, Robinson A. Enhanced antenatal detection of group B streptococcus colonization. Obstet Gynecol 1995;85:437-439
35. Honest H, Sharma S, Khan KS. Rapid tests for group B streptococcus colonization in laboring women: a systematic review. Pediatrics 2006;117:1055-1066 (Pubitemid 46071496)
36. Brady K, Duff P, Schilhab JC, Herd M. Reliability of a rapid latex fixation test for detecting group B streptococci in the genital tract of parturients at term. Obstet Gynecol 1989;73:678-681
37. Ryan KM, Lencki SG, Elder BL, Northern WI, Khamis HJ, Bofill JA. DNA probe for beta-hemolytic group B streptococcus. Diagnostic accuracy in threatened preterm labor. J Reprod Med 1999;44:587-591
38. Bergeron MG, Ke D, Menard C, Picard FJ, Gagnon M, Bernier M, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000;343:175-179 (Pubitemid 30489214)
39. Davies HD, Miller MA, Faro S, Gregson D, Kehl SC, Jordan JA. Multicenter study of a rapid molecular-based assay for the diagnosis of group B streptococcus colonization in pregnant women. Clin Infect Dis 2004;39:1129-1135 (Pubitemid 40169309)
40. Baker CJ. Inadequacy of rapid immunoassays for intrapartum detection of group B streptococcal carriers. Obstet Gynecol 1996;88:51-55 (Pubitemid 26197276)
41. Nguyen TM, Gauthier DW, Myles TD, Nuwayhid BS, Viana MA, Schreckenberger PC. Detection of group B streptococcus: comparison of an optical immunoassay with direct plating and broth-enhanced culture methods. J Matern Fetal Med 1998;7:172-176 (Pubitemid 28385530)
42. Park CH, Ruprai D, Vandel NM, Hixon DL, Mecklenburg FE. Rapid detection of group B streptococcal antigen from vaginal specimens using a new optical immunoassay technique. Diagn Microbiol Infect Dis 1996;24:125-128 (Pubitemid 27089164)
43. Smaill F. Intrapartum antibiotics for group B streptococcal colonisation. Cochrane Database Syst Rev 1996;1:CD000115.
44. Morales WJ, Lim DV, Walsh AF. Prevention of neonatal group B streptococcal sepsis by the use of a rapid screening test and selective intrapartum chemoprophylaxis. Am J Obstet Gynecol 1986;155:979-983 (Pubitemid 17176660)
45. Tuppurainen N, Hallman M. Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients. Obstet Gynecol 1989;73:583-587 (Pubitemid 19086968)
46. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986;314:1665-1669 (Pubitemid 16097843)
47. Easmon CS, Hastings MJ, Deeley J, Bloxham B, Rivers RP, Marwood R. The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci. Br J Obstet Gynaecol 1983;90:633-635
48. Matorras R, Garcia-Perea A, Omenaca F, Diez-Enciso M, Madero R, Usandizaga JA. Intrapartum chemoprophylaxis of early-onset group B streptococcal disease. Eur J Obstet Gynecol Reprod Biol 1991;40:57-62.
49. Illuzzi JL, Bracken MB. Duration of intrapartum prophylaxis for neonatal group B streptococcal disease: a systematic review. Obstet Gynecol 2006;108:1254-1265 (Pubitemid 44665425)
50. Woodgate J, Flenady V, Steer P. Intramuscular penicillin for the prevention of early onset group B streptococcal infection in newborn infants. Cochrane Database Syst Rev 2004;2:CD003667.
51. Pyati SP, Pildes RS, Jacobs NM, Ramamurthy RS, Yeh TF, Raval DS, et al. Penicillin in infants weighing two kilograms or less with early-onset group B streptococcal disease. N Engl J Med 1983;308:1383-1389
52. Steigman AJ, Bottone EJ, Hanna BA. Intramuscular penicillin administration at birth: prevention of early-onset group B streptococcal disease. Pediatrics 1978;62:842-844 (Pubitemid 9009899)
53. Lloyd DJ, Belgaumkar TK, Scott KE, Wort AJ, Aterman K, Krause VW. Prevention of group-B beta-haemolytic streptococcal septicaemia in low-birthweight neonates by penicillin administered within two hours of birth. Lancet 1979;1:713-715
54. Patel DM, Leblanc MH, Morrison JC, Graves GR, Glick CG, Martin JN, Jr, et al. Postnatal penicillin prophylaxis and the incidence of group B streptococcal sepsis in neonates. South Med J 1994;87:1117-1120 (Pubitemid 24347138)
55. Siegel JD, Cushion NB. Prevention of early-onset group B streptococcal disease: another look at single-dose penicillin at birth. Obstet Gynecol 1996;87:692-698
56. American College of Obstetrics and Gynecology. Prevention of early-onset group B streptococcal disease in newborns. ACOG Committee Opinion No. 173. Washington, DC: American College of Obstetrics and Gynecology; 1996.
57. Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol 1998;179:879-883 (Pubitemid 28489273)
58. Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset Escherichia coli disease. The effect of intrapartum ampicillin. Arch Pediatr Adolesc Med 1998;152:35-40. (Pubitemid 28098937)
59. PHLS Group B Streptococcus Working Group. Commun Dis Rep CDR Wkly 1998;8:439, 442.
60. PHLS Group B Streptococcus Working Group. Interim 'good practice' recommendations for the prevention of early-onset neonatal group B streptococcal (GBS) infections in the UK. London: Public Health Laboratory Service; 2001.
61. Royal College of Obstetricians and Gynaecologists. Prevention of early-onset neonatal group B streptococcal disease. RCOG Guideline No. 36. London: RCOG; 2003.
62. Health Protection Agency GBS Working Group. Interim 'good practice' recommendations for the prevention of early-onset neonatal group B streptococcal (GBS) infections in the UK. London: Health Protection Agency; 2004.
63. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep 1996;45:1-24.
64. Larsson C, Lindroth M, Nordin P, Stalhammar-Carlemalm M, Lindahl G, Krantz I, et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 2006;91:F403-8.
65. Lewis DB, Wilson CB. Developmental immunology and the role of host defenses in fetal and neonatal susceptibility to infection. In Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant, 5th edn. Philidelphia, PA: WB Saunders; 2001.
66. Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, Grandi G, et al. Group B streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006;4:932-942 (Pubitemid 44768255)
67. Hughes MJ, Wilson R, Moore JC, Lane JD, Dobson RJ, Muckett P, et al. Novel protein vaccine candidates against group B streptococcal infection identified using alkaline phosphatase fusions. FEMS Microbiol Lett 2003;222:263-271 (Pubitemid 36589004)
68. Emergent BioSolutions. Group B streptococcus vaccine - product candidate. 2007. URL: www.emergentbiosolutions.com/html/streptococcus-vaccine.aspx.
69. Colbourn T, Asseburg C, Bojke L, Philips Z, Claxton K, Gilbert R. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: costeffectiveness and expected value of information analyses. Health Technol Assess 2007;11(29).
70. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20. (Pubitemid 30020655)
71. Centers for Disease Control and Prevention. Early-onset and late-onset neonatal group B streptococcal disease: United States, 1996-2004. MMWR Morb Mortal Wkly Rep 2005;54:1205-1208
72. Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002;347:233-239 (Pubitemid 34787629)
73. Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988;18:515-540 (Pubitemid 19000201)
74. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002;347:240-247 (Pubitemid 34787630)
75. Cheng PJ, Shaw SW, Lin PY, Huang SY, Soong YK. Maternal anxiety about prenatal screening for group B streptococcus disease and impact of positive colonization results. Eur J Obstet Gynecol Reprod Biol 2006;128:29-33.
76. Darbyshire P, Collins C, McDonald HM, Hiller JE. Taking antenatal group B streptococcus seriously: women's experiences of screening and perceptions of risk. Birth 2003;30:116-123
77. Patten S, Vollman AR, Manning SD, Mucenski M, Vidakovich J, Davies HD. Vaccination for group B streptococcus during pregnancy: attitudes and concerns of women and health care providers. Soc Sci Med 2006;63:347-358 (Pubitemid 43776585)
78. McLaughlin K, Crowther C. Universal antenatal group B streptococcus screening? The opinions of obstetricians and neonatologists within Australia. Aust N Z J Obstet Gynaecol 2000;4:338-340
79. Gosling I, Stone P, Grimwood K. Awareness, knowledge and attitudes of lead maternity carers towards early-onset neonatal group B streptococcal disease. N Z Med J 2002;115:106-108 (Pubitemid 34240259)
80. Consort. The STARD initiative - towards complete and accurate reporting of studies on diagnostic accuracy. 2007. URL: www.consort-statement.org/ Initiatives/newstard.htm.
81. Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 2003;56:1118-1128 (Pubitemid 37386337)
82. Adriaanse AH, Kollee LA, Muytjens HL, Nijhuis JG, de Haan AF, Eskes TK. Randomized study of vaginal chlorhexidine disinfection during labor to prevent vertical transmission of group B streptococci. Eur J Obstet Gynecol Reprod Biol 1995;61:135-141
83. Brady K, Sizemore KL, Duff P, Aamodt LW. The effect of bacteriostatic lubricant on group B streptococcal cultures of the female genital tract. Obstet Gynecol 1989;74:848-850 (Pubitemid 20003272)
84. Baker CJ, Clark DJ, Barrett FF. Selective broth medium for isolation of group B streptococci. Appl Microbiol 1973;26:884-885
85. Hammoud MS, Al-Shemmari M, Thalib L, Al-Sweih N, Rashwan N, Devarajan LV, et al. Comparison between different types of surveillance samples for detection of GBS colonization in both parturient mothers and their infants. Gynecol Obstet Invest 2003;56:225-230 (Pubitemid 37505855)
86. Fowlie PW, Schmit B. Diagnostic tests for bacterial infection from birth to 90 days - a systematic review. Arch Dis Child Fetal Neonatal Ed 1998;78:F92-8.
87. Thompson PJ. Congenital bacterial sepsis in very preterm infants. J Med Microbiol 1992;36:117-120
88. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763-770
89. Alonzo TA, Pepe MS, Moskowitz CS. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat Med 2002;21:835-852
90. Bachmann LM, Puhan MA, ter Riet G, Bossuyt PM. Sample sizes of studies on diagnostic accuracy: literature survey. Br Med J 2006;332:1127-1129
91. Dawid AP. Properties of diagnostic data distributions. Biometrics 1976;32:647-658
92. Miettinen OS, Henschke CI, Yankelevitz DF. Evaluation of diagnostic imaging tests: diagnostic probability estimation. J Clin Epidemiol 1998;51:1293-1298 (Pubitemid 29009530)
93. Bachmann LM, Khan KS, Ogah J, Owen P. Multivariable analysis of tests for the diagnosis of intrauterine growth restriction. Ultrasound Obstet Gynaecol 2003;21:370-374 (Pubitemid 36555116)
94. Harrell FE, Jr, Lee KL, Pollock BG, Harrell FEJ, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst 1988;80:1198-1202
95. Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD, Steyerberg EW, et al. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med 2000;19:141-160
96. Concato J, Feinstein AR, Holford TR, Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-210
97. Khan KS, Chien PF, Dwarakanath LS. Logistic regression models in obstetrics and gynecology literature. Obstet Gynecol 1999;93:1014-1020 (Pubitemid 29247114)
98. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-1379
99. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
100. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Br Med J 2003;326:41-44
101. Hussain-Gambles M, Leese B, Atkin K, Brown J, Tovey P. Involving South Asian patients in clinical trials. Health Technol Assess 2004;8(42).
102. Office for National Statistics. Preterm births, England and Wales. 2007. URL: www.statistics.gov.uk/Statbase/Product.asp?vlnk=14882.
103. Thomas J, Paranjothy S. The national sentinel Caesarean section audit report. London: RCOG Press; 2001.
104. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202. (Pubitemid 38155650)
105. Knowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. Health Technol Assess 2005;9(44).
106. Marteau TM. Psychological consequences of screening for Down's syndrome. Br Med J 1993;307:146-147 (Pubitemid 23199975)
107. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess 1998;2:1-112.
108. Gross H, Pattison H. Sanctioning pregnancy: a psychological perspective on the paradoxes and culture of research. London: Routledge; 2007. pp. 12-19.
109. Green J, Statham H. Testing for fetal abnormality in routine antenatal care. Midwifery 1993;9:124-135
110. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 2004;8(33).
111. Davis A, Bamford J, Wilson I, Ramkalawan T, Forshaw M, Wright S. A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment. Health Technol Assess 1997;1(10).
112. Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Prescott RJ. Uptake and acceptability of antenatal HIV testing: randomised controlled trial of different methods of offering the test. Br Med J 1998;316:262-267
113. Jha S, Gee H, Coomarasamy A. Women's attitudes to HIV screening in pregnancy in an area of low prevalence. Br J Obstet Gynaecol 2003;110:145-148 (Pubitemid 36263110)
114. Townsend CL, Cliffe S, Tookey PA. Uptake of antenatal HIV testing in the United Kingdom: 2000-2003. J Public Health 2006;28:248-252
115. Ware JEJ, Snyder MK, Wright WR. Defining and measuring patient satisfaction with medical care. Eval Program Plann 1983;6:247-263
116. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychology 1992;31:301-306
117. Watkin PM, Baldwin M, Dixon R, Beckman A. Maternal anxiety and attitudes to universal neonatal hearing screening. Br J Audiol 1998;32:27-37. (Pubitemid 28121206)
118. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60:631-637
119. Fink P, Ewald H, Jensen J, Sorensen L, Engberg M, Holm M, et al. Screening for somatization and hypochondriasis in primary care and neurological inpatients. A seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999;46:261-273 (Pubitemid 29118388)
120. Braun V, Clarke V. Using thematic analysis in psychology. Q Res Psychol 2006;3:77-101.
121. Curtis L, Netten A. Costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2006.
122. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - introduction. Health Technol Assess 2004;8(11).
123. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002;51(RR-11):1-22.
124. Ramus RM, McIntire DD, Wendel GD, Jr. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term. Am J Obstet Gynecol 1999;180(Suppl.1):S85.
125. Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77.
126. Office for National Statistics. Mortality statistics: childhood, infant and perinatal (Series DH3 no.38). 2005. URL: www.statistics.gov.uk/statbase/ Product.asp?vlnk=6305.
127. Weisner AM, Johnson AP, Lamagni TL, Arnold E, Warner M, Heath PT, et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 2004;38:1203-1208 (Pubitemid 38608558)
128. Department of Health. Reference costs 2006-2007 collection: costing and activity guidance and requirements. 2007. URL: www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-074072.
129. NHS. NHS pay - agenda for change - pay rates. 2007. URL: www.nhscareers.nhs.uk/details/Default.aspx?Id=766.
130. NICE. Guide to the methods of technology appraisal (reference N0515). 2004. URL: www.nice.org.uk/page.aspx?o=201973.
131. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006;6:1-8.
132. Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig MJ, Bartels DB, et al. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 2006;117:e1139-45.
133. Cromwell D, Joffe T, van der Meulen J, Dhillon C, Hughes R, Murphy D. The prevention of early-onset neonatal group B streptococcal disease in UK obstetric units: an audit of reported practice in England, Scotland, Wales and Northern Ireland. London: Royal College of Obstetrics and Gynaecology; 2007.
134. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-585 (Pubitemid 15046383)
135. Department of Health. Maternity matters: choice, access and continuity of care in a safe service. London: Department of Health; 2007.
136. de Azavedo JCS, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001;45:3504-3508 (Pubitemid 33107869)
137. Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis. Pediatr Infect Dis J 2006;25:939-940
138. Edwards MS. Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 2006;17:149-152
139. Breindel B. Point of care diagnostics. Report No. HLC043A. Wellesley, MA, USA: BCC Research; 2006.
140. Food and Drugs Administration. CLIA categorization criteria. 2001. URL: www.fda.gov/cdrh/clia/categorization.html.
141. Campbell S, Klein RB. Waived tests and testing. Clin Microbiol Newsl 2006;28:89-93.
142. Medical Devices Agency. Management and use of IVD point of care test devices. Report No. MDA DB2002(03). London: Medical Devices Agency; 2002.
143. Cramb R. Guidelines on point-of-care testing. London: Royal College of Pathologists; 2004.
144. Institute of Biomedical Sciences. Point of care testing (near patient testing): guidance on the involvement of the clinical laboratory. London: Institute of Biomedical Sciences; 2004.
145. Centers for Disease Control. Good laboratory practices for waived test sites. Survey findings from testing sites holding a certificate of waiver under the Clinical Laboratory Improvement Amendments of 1988 and recommendations for promoting quality testing. MMWR Morb Mortal Wkly Rep 2005;54:RR-13.
146. Sydes MR, Spiegalhalter DJ, Altman DG, Babiker AB, Parmar MKB, and the DAMOCLES group. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials 2004;1:60-79.
147. NHS Health Technology Assessment Programme. 2007. URL: www.ncchta.org/index.shtml.
148. Medical Research Council (MRC). MRC guidelines for good clinical practice. London: Medical Research Councils Publications Department; 1998.
149. International Conference on Harmonisation. Guidelines for good clinical practice. Report No. E6(R1). International Conference on Harmonisation Secretariat, Geneva; 1996.
150. US Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. Rockville, MD: FDA; 2001.
151. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, et al. Issues in data monitoring and interim analysis of trials (DAMOCLES project). Health Technol Assess 2003;9(7).
152. SCT Working Group on Data Monitoring, Dixon DO, Freedman RS, Herson J, Kim KM, Silverman MH, et al. Guidelines for the data and safety monitoring for clinical trials not requiring traditional data monitoring committees. Clin Trials 2006;3:314-319
153. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ 1986;134:587-594 (Pubitemid 16099651)
154. Ellenberg S, Fleming T, DeMets D. Data monitoring committees in clinical trials: a practical perspective. Chichester: John Wiley; 2002.
155. Workshop on early stopping rules in cancer clinical trials. Stat Med 1993;13:1289-1499
156. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med 2002;137:598-602.
157. Whiting P, Rutjes AWS, Dinnes J, Reitsma JB, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8(25).
158. Khan KS, Dinnes J, Kleijnen J. Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol 2001;95:6-11.
159. Thornton JG, Lilforf RJ. Do we need randomised trials of antenatal tests of fetal wellbeing? Br J Obstet Gynaecol 1993;100:197-200.
160. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Methodological research in diagnostic tests: evaluation of diagnostic tests when there is no gold standard - a review of methods. Health Technol Assess 2007;11(50):iii,ix- 51.
161. Cheng H, Macalouso M. Comparison of the accuracy of two tests with a confirmatory procedure limited to positive results. Epidemiology 1997;8:104-106 (Pubitemid 27014230)
162. Chock C, Irwig L, Berry G, Glasziou P. Comparing dichotomous screening tests when individuals negative on both tests are not verified. J Clin Epidemiol 1997;50:1211-1217
163. Walter SD. Estimation of test sensitivity and specificity when disease confirmation is limited to positive results. Epidemiology 1999;10:67-72.
164. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-210
165. Miettinen OS, Henschke CI, Yankelevitz DF. Evaluation of diagnostic imaging tests: diagnostic probability estimation. J Clin Epidemiol 1998;51:1293-1298
166. Drummond M, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edn. Oxford: Oxford University Press; 1997.
167. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary (BNF). No.53, March 2007. London: BMA and RPS; 2007